Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 2,270,000 shares, a decline of 27.9% from the May 15th total of 3,150,000 shares. Based on an average daily trading volume, of 381,600 shares, the short-interest ratio is currently 5.9 days. Currently, 8.7% of the company's shares are sold short.

Verrica Pharmaceuticals Stock Performance

NASDAQ:VRCA opened at $0.64 on Wednesday. The firm has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.63. Verrica Pharmaceuticals has a one year low of $0.38 and a one year high of $8.98. The firm has a market cap of $59.33 million, a P/E ratio of -0.53 and a beta of 1.75.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The business had revenue of $3.44 million during the quarter, compared to the consensus estimate of $2.53 million. On average, research analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caligan Partners LP bought a new stake in Verrica Pharmaceuticals during the fourth quarter valued at about $5,201,000. Boothbay Fund Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter valued at about $1,811,000. Geode Capital Management LLC lifted its position in shares of Verrica Pharmaceuticals by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock valued at $334,000 after buying an additional 21,789 shares during the last quarter. Heights Capital Management Inc. bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $246,000. Finally, Rhumbline Advisers grew its position in shares of Verrica Pharmaceuticals by 975.2% in the 4th quarter. Rhumbline Advisers now owns 266,093 shares of the company's stock worth $186,000 after buying an additional 241,344 shares during the last quarter. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on VRCA. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Needham & Company LLC reissued a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Verrica Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.00.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.